Related Experiment Video
Updated: Jan 30, 2026
Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
Published on: December 23, 2014
The Efficacy of Systemic Doxycycline Administration as an Inhibitor of Intimal Hyperplasia after Balloon Angioplasty
Deidra J H Mountain1, Stacy S Kirkpatrick1, Joshua D Arnold1
1Department of Surgery, University of Tennessee Graduate School of Medicine, Knoxville, TN.
Background:
Intimal hyperplasia (IH) is the most common indicator for secondary intervention in peripheral vascular disease. Matrix metalloproteinases (MMPs) play a role in IH development due to their degradation of the extracellular matrix. Doxycycline (Doxy), a member of the tetracycline family of antibiotics, is a potent MMP inhibitor. We have previously shown that Doxy inhibits MMP activity and vascular smooth muscle cell migration in vitro. We hypothesized that Doxy would decrease MMP activity in vivo and inhibit the development of IH in a rodent model of vascular injury.
Methods And Results:
Doxy (400 mg/pellet) was delivered by a slow-release pellet implanted 3 days prior to or at the time of balloon angioplasty (BA) of the common carotid artery in female rats. At 14 days post-BA, intima-to-media (I:M) ratios were 0.77 ± 0.21 and 1.04 ± 0.32 in the Doxy treated groups, respectively, compared to 1.25 ± 0.26 in the control group (P = not significant; n = 3). Additionally, the tested dose of Doxy in either group had no inhibitory effect on membrane type 1-MMP or MMP-2 tissue levels, as measured by immunohistochemistry, or on systemic levels of MMP, as measured by total MMP serum levels using enzyme-linked immunosorbent assay. At 14 days post-BA, VSMC proliferation in the injured artery was increased to Doxy treatment prior to and at the time of surgery (23.5 ± 3.4 and 27.2 ± 3.9%, respectively), compared to control (11.4 ± 0.4%; n = 3), as measured by proliferating cellular nuclear antigen immunostaining.
Conclusions:
In our in vivo model of vascular injury, systemic Doxy administration prior to or at the time of vascular injury does not significantly hinder the progression of IH development. Additional doses and routes of administration could be examined in order to correlate therapeutic serum levels of Doxy with effective MMP inhibition in serum and arterial tissue. However, alternative drug delivery systems are needed in order to optimize therapeutic administration of targeted MMP inhibitors for the prevention of IH development.
Insights
Doxycycline did not significantly inhibit intimal hyperplasia in a rodent model of vascular injury. Further research into drug delivery methods is needed for effective matrix metalloproteinase inhibition.
Area of Science:
- Vascular Biology
- Pharmacology
- Biochemistry
Background:
- Intimal hyperplasia (IH) is a key factor in peripheral vascular disease.
- Matrix metalloproteinases (MMPs) contribute to IH by degrading extracellular matrix.
- Doxycycline (Doxy), an MMP inhibitor, showed promise in vitro for inhibiting IH.
Purpose of the Study:
- To investigate the in vivo efficacy of Doxycycline in reducing MMP activity and inhibiting IH development.
- To evaluate the effect of Doxycycline on vascular smooth muscle cell proliferation post-injury.
Main Methods:
- Doxycycline was administered via slow-release pellets to rats before or during balloon angioplasty.
- Intima-to-media ratios were measured 14 days post-injury.
- MMP levels and vascular smooth muscle cell proliferation were assessed using immunohistochemistry and ELISA.
Main Results:
- Doxycycline treatment did not significantly reduce intima-to-media ratios compared to controls.
- No significant inhibition of MMP-1, MMP-2, or systemic MMP levels was observed.
- Vascular smooth muscle cell proliferation was increased in Doxycycline-treated groups.
Conclusions:
- Systemic Doxycycline administration did not significantly prevent IH progression in this in vivo model.
- Optimizing drug delivery systems is crucial for effective MMP inhibition and IH prevention.
- Further studies should explore different doses and administration routes for Doxycycline.
More Related Videos
07:32Balloon-based Injury to Induce Myointimal Hyperplasia in the Mouse Abdominal Aorta
Published on: February 7, 2018
07:02A Rabbit Venous Interposition Model Mimicking Revascularization Surgery using Vein Grafts to Assess Intimal Hyperplasia under Arterial Blood Pressure
Published on: May 15, 2020
Related Concept Videos
01:11Overview of Systemic Arteries
Systemic circulation is the part of the cardiovascular system that carries oxygenated blood away from the heart to the body's tissues and returns deoxygenated blood back to the...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:29Self-Efficacy
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Second Order systems II